BPMUF Recent News Astellas Secures Exclusive Righ
Post# of 4
Astellas Secures Exclusive Rights to Commercialize Isavuconazole in the U.S. and Canada PR Newswire - Fri Feb 28, 6:00AM CST
Basilea swaps its isavuconazole North American co-promote rights for full isavuconazole rights outside of North America GlobeNewswire - Fri Feb 28, 12:20AM CST
Basilea reports that isavuconazole receives Qualified Infectious Disease Product designation from U.S. FDA for the treatment of invasive mucormycosis GlobeNewswire - Thu Feb 27, 12:21AM CST
Skin And Soft Tissue Infections - Pipeline Review, H2 2013 Research Report M2 - Tue Feb 18, 2:21AM CST
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013 Research Report M2 - Mon Feb 03, 2:25AM CST
Basilea reports that isavuconazole receives Qualified Infectious Disease Product (QIDP) designation from U.S. FDA for the treatment of invasive aspergillosis GlobeNewswire - Tue Dec 03, 12:19AM CST
Inflammatory Bowel Disease - Pipeline Review, H2 2013 M2 - Tue Nov 19, 3:30AM CST